<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884376</url>
  </required_header>
  <id_info>
    <org_study_id>10-009</org_study_id>
    <nct_id>NCT01884376</nct_id>
  </id_info>
  <brief_title>Clinical Study for the Treatment of Peripheral Nerve Defects With Neuromaix</brief_title>
  <acronym>PeRepair</acronym>
  <official_title>Klinische Interventionsstrategie Zur überbrückenden Behandlung Peripherer Nervendefekte Mit Neuromaix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the development and initial clinical application of the nerve guide
      Neuromaix in humans to provide evidence for the safety and performance of the device.

      Neuromaix is intended to be used as a guiding structure to bridge a peripheral nerve
      discontinuity, and to create a conduit for axonal growth across the nerve gap.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Neuromaix nerve guide is an absorbable implant composed of porcine collagen, used to
      bridge a peripheral nerve discontinuity, and to create a conduit for axonal growth across the
      nerve gap. Neuromaix provides a protective environment for peripheral nerve regeneration
      after injury. Neuromaix connects the proximal and distal ends of a transected nerve, allowing
      regenerating axons to grow through the scaffold, into the distal nerve tissue towards the
      target muscle or skin.

      Neuromaix is composed of two parts. The Epimaix part provides the structural characteristics
      needed to suture the nerve guide in place and to prevent ingrowth of scar tissue. The
      Perimaix part provides a structure that mimics endoneurial tubes, providing guidance for the
      regenerating axons while bridging the nerve gap.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proof of safety of the medical device Neuromaix</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective is the proof of safety of the medical device Neuromaix. key parameter: normal wound healing without complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effectiveness evaluation of the implant device Neuromaix</measure>
    <time_frame>12 months</time_frame>
    <description>The secondary objective is the evaluation of the effectiveness of the Neuromaix implantation (&quot;Performance arm of study&quot;).
key parameters: axonal regeneration and recovery of sensory function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Patients With a Scheduled (Diagnostic) Nervus Suralis Biopsy</condition>
  <arm_group>
    <arm_group_label>Neuromaix implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of Neuromaix during an diagnostic nerve biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuromaix</intervention_name>
    <arm_group_label>Neuromaix implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both genders in the age between 18 und 70 years

          -  patients who are scheduled for a nerve biopsy

        Exclusion Criteria:

          -  alcohol-related polyneuropathy

          -  paraneoplastic polyneuropathy

          -  present: immunosuppressive therapy

          -  present: malignant tumor

          -  peripheral vascular diseases

          -  collagen diseases (e.g. existing keloid scars)

          -  patients with an increased wound healing disorder (e.g. diabetics)

          -  patients with chronic venous insufficiency (vein thrombosis, skin diseases)

          -  patients with coagulation and bleeding disorders (ASA- or Marcumar-patients)

          -  present: pregnancy

          -  HIV, Hepatitis B or Hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmet Bozkurt, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Plastic Surgery, Hand Surgery and Burn Center,University Hospital RWTH Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Plastic Surgery, Hand Surgery and Burn Center, University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nerve biopsy</keyword>
  <keyword>nerve regeneration</keyword>
  <keyword>neuroma pain</keyword>
  <keyword>loss of sensation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

